SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Milacron Holdings Corp. – MCRN

BALA CYNWYD, July 15, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Milacron Holdings Corp. (“Milacron” or “the Company”) (NYSE – MCRN -News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Hillenbrand Corp. (“Hillenbrand”).

Under the terms of the transaction, Milacron shareholders will receive only $11.80 in cash and a fixed exchange ratio of 0.1612 of a share of Hillenbrand for each share of Milacron stock they own. The transaction values Milacron at only $18.07 per share. The investigation concerns whether the Board of Milacron breached their fiduciary duties to shareholders and whether Hillenbrand is underpaying for the Company. The transaction may undervalue the Company and would result in a loss for many Milacron shareholders. For example, Milacron stock has traded at $21.43 per share and an analyst has set a $19.00 per share price target for the stock.

If you own shares of Milacron stock and wish to discuss the legal ramifications of  the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.